LOXL2 and head and neck squamous cell carcinoma: Taken together, these results suggest that serum exosome LOXL2 levels are only associated with early-stage HNSCC, and may serve as biomarkers for early diagnosis and a potential target for therapeutic intervention (Cox et al., 2016; Sanada et al., 2020).